Levosimendan Kalceks (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances myocardial contractility without raising intracellular calcium concentrations. At the same time, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that lowers preload and afterload, thereby improving overall cardiac output.

The dosing regimen for levosimendan is determined by the treating physician based on the patient’s clinical condition, severity of heart failure, and response to therapy. The prescriber will set the infusion rate, duration, and any loading dose according to established guidelines and individual patient needs.

Safety data for levosimendan during pregnancy and lactation are limited. Because potential risks cannot be excluded, the drug should only be used if the potential benefit justifies the possible harm to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Levosimendan Kalceks. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Unlike traditional calcium‑increasing inotropes, levosimendan enhances contractility by sensitising troponin C to existing calcium, which reduces the risk of calcium‑mediated toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that can be advantageous over agents such as dobutamine or dopamine in certain clinical scenarios.

Levosimendan Kalceks should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging until use. The solution must be inspected for particulate matter or discoloration before administration, and any unused portion should be discarded according to local regulations.

Levosimendan Kalceks is given as an intravenous infusion under continuous cardiac and haemodynamic monitoring. The infusion may be started with or without a loading dose, followed by a maintenance infusion over several hours, as directed by the prescribing clinician based on the patient’s response and tolerance.

The most serious adverse events include severe hypotension, ventricular arrhythmias, myocardial ischaemia, and rare allergic reactions such as anaphylaxis. Clinicians should monitor blood pressure, heart rhythm and ECG changes closely throughout the infusion and be prepared to intervene promptly if any of these complications arise.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals with significant obstructive cardiac lesions where increased contractility could be harmful. Caution is also advised in patients with severe renal or hepatic impairment, and it should be avoided in pregnancy unless absolutely necessary.